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Objectives: 
                   To assess the correlation of the comorbid illness and inflammatory 
markers with outcome of patient initiated on maintenance dialysis. 
Patients and Methods: 
                         This is a prospective observational study on end stage renal disease 
patients initiated on maintenance haemodialysis in department of nephrology, CMC 
Vellore, from July 2009 to December 2010. Patients with less than 6 months of follow 
up, or on treatment with anti inflammatory drugs, or positive for hepatitis B or C virus 
or HIV were excluded from this study. Patient was divided into 3 groups based on the 
comorbidities according to Davies comorbidity scores. The comorbidity score for 
each patient was calculated depending on the number of following domains: diabetes 
mellitus, malignancy, ischemic heart disease, peripheral vascular disease, left 
ventricular dysfunction, systemic collagen vascular disease, and other significant 
pathology. The grade of comorbidity was obtained from the total scores. Grade 0 is 
zero score, Grade 2 is score of one or two, and Grade 3 is score of three or more. 
Information about comorbid illness was obtained from clinical examination, medical 
records, lab parameters, ECG and echocardiography. Baseline lab tests including 
hsCRP and IL6 samples were taken before the initiation of maintenance dialysis. 
Patients were treated with thrice weekly standard bicarbonate dialysis and their 
clinical events were recorded accurately. Laboratory parameters were repeated every 
third month during the follow up period. Patients were prospectively followed up 
during the study period. 
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Results: 
                     The mean age at initiation of maintenance dialysis was 52.72 ± 11.25 
and males constituted the majority of patients (77.5%). Mean BMI of the patients was 
21.15 ± 2.44. Diabetic nephropathy was the commonest native kidney disease 
(47.5%) followed by unknown native kidney disease in 35% of patients. Hypertension 
was present in 92.5% at the time of initiation of haemodialysis. Mean eGFR at 
initiation of dialysis was 5.66 ± 2.29 ml/min/BSA. Median follow up period was 310 
(180 – 546) days. Hypotension was the commonest clinical event during follow up. 
About 25% of patients had one or more infection episodes with sepsis and access 
related infection being the commonest cause. 40% of patients had one or more 
episode of AV fistula failure during follow up of which 50% was due to primary AVF 
failure. During follow up death occurred in 10% of patients with cause of death being 
infection related in majority of patients followed by cardiac cause. Associated 
comorbid illness and baseline inflammatory markers IL6 and hsCRP were 
significantly higher in this group of patients.  
 
Conclusions:  
                  Comorbid illness and higher baseline inflammatory markers is a poor 
prognostic marker in maintenance haemodialysis patients. Measurement of baseline 
inflammatory markers level should be considered for patients initiating on 
maintenance dialysis for risk stratification and prognostification.  
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            Chronic inflammation is highly prevalent in end stage renal disease and is a 
major contributing factor for high mortality and morbidity in this population.  Chronic 
inflammatory state will leads to endothelial injury which is considered as critical 
event in pathogeneses of atherosclerosis. Persistent inflammation in these patients is 
associated with various complications like cardiovascular mortality, atherosclerosis, 
malnutrition syndrome, higher hospitalization rates (1). Recent attention has focused 
on the inflammatory state as the cause of progression of underlying comorbid illness 
which leads to increased mortality in end stage renal disease. Reactivation of 
inflammatory cascade during the dialysis is associated with decreased survival (2). 
Inflammation plays a major role in arterial damage of dialysis patients. Underlying 
disease, retention of inflammatory mediators, auto-oxidation products, repeated 
exposure to dialysis filters and low grade infections are the probable factors for the 
inflammatory state. 
                   Acute phase reactants include a class of proteins like C-reactive protein 
which are secreted mainly by hepatocyes under stimulation of various cytokines like 
interleukin 6. Inflammatory markers like C-reactive protein and interleukin 6 is 
elevated in dialysis patients. C-reactive protein is having a direct proinflammatory 
effect on human endothelial cell by inducing adhesion molecule expression. 
Interleukin 6 is a potent proatherogenic cytokine which can be demonstrated by the 
increased expression of interleukin 6 at the fibrous plaque stage of the atherosclerosis 
process (3). The measurement of these inflammatory markers might be useful for 
predicting survival in dialysis patients. Whether severity of inflammation as measured 
by these markers will gives prognostic information on patients on dialysis in our 
population is not yet studied.  
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                        In the present prospective observational study, we analyzed the clinical 
and laboratory parameters of patient initiated on maintenance haemodialysis in our 
institution and followed up to assess the correlation between the comorbid illness and 
inflammatory markers with outcome.   
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                   End – stage renal disease is associated with high morbidity and mortality 
rates (4) . Even with improvement in dialysis technology the mortality and morbidity 
in end stage renal disease is very high. Cardiovascular disease is the main cause of 
mortality in end stage renal disease. The mortality  of patients on dialysis is very high 
which is about 10-20% when compared with that of general population even when 
adjusted for age, gender and other co morbidities(5). The cardiovascular mortality 
accounts for about annual mortality of 9% which is about 10 to 20 fold higher than 
general population (6). Inflammation strongly predicts the all cause and 
cardiovascular mortality in patients on dialysis.(7). About 30 to 50% of patients on 
dialysis have elevated level of inflammatory markers.  
                              Renal insufficiency is associated with accelerated atherosclerosis. 
Ishimura et al has shown that renal failure is a significant and independent risk factor 
for carotid atherosclerosis (8). The pathogenesis of atherosclerosis in end stage renal 
disease patients can be well explained by Ross theory (9). Endothelial activation is 
induced by any insult or risk factor which affects the vascular endothelium. This will 
leads to expression of E – selectin and adhesion molecules which include intracellular 
adhesion molecule -1 and vascular adhesion molecule -1.Macrophages and monocytes 
will be attracted to the altered endothelium. Later they will infiltrate the vessel wall 
and will initiate the inflammatory process. Monocytes will produce both pro and anti 
– inflammatory cytokines. The pro inflammatory cytokines includes interleukin-1β, 
IL-6, and tumour necrosis factor α. They induce the synthesis of acute phase reactant, 
C – reactive protein from the liver. CRP is both cardiovascular and direct risk factor 
for atherosclerosis. On activation of IL-6 sensitive sequence in the fibrinogen gene 
promoter, fibrinogen is produced. Fibrinogen links the inflammation to clot 
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formation. More than half of  the patients on dialysis is having  elevated plasma 
fibrinogen levels (10).  
 
Causes of inflammation: 
                       The causes of inflammations in patient on haemodialysis are 
multifactorial and includes patient related factors and haemodialysis related factors ( 
See table 1). 
  
Table 1. Causes of inflammation in hemodialysis 
Patient related  
    Underlying disease 
    Comorbidity , Peripheral vascular disease 
    Oxidative stress 
    Ca × P metabolism (Calcification, Fetuin – A ) 
    Infection ( apparent and non – apparent ) 
                   Helicobacter Pylori 
                   Chlamydia Pneumoniae 
                   Peridonditis  
                   Tuberculosis and others 
                   Vascular access 
    Immunologic 
                   Genetic 
                   Nonfunctioning kidney transplants 
    Encapsulating peritoneal sclrosis 
    Anemia  ( hepcidin ) 
    Heart failure 
    Obesity 
    Tumors 
    Physical exercise – sedentary life style 
Dialysis technique related 
     Retention of inflammatory mediators 
     Oxidative imbalance 
     Acetate 
     Pyrogenic substances of the dialysate  
     Complement activation, membranes and other material 
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                Inflammation in dialysis patients may be due to renal failure itself or may 
be a consequence of dialysis or may be unrelated to both ie infectious cause. About 
15% of deaths in end stage renal disease are attributable to infectious cause. 
Renal failure:  
             Patients with renal failure are having elevated level of inflammatory markers 
even before initiating dialysis. Stenvinkel has shown from various studies the 
prevalence of elevated C reactive protein of about 35% in patients with renal failure 
without dialysis and more than 50% in patient on dialysis (11). Kidney is the major 
site of elimination of cytokines. Accumulation of inflammatory mediators in renal 
failure can results in inflammation. Reduced elimination of inflammatory mediators 
can lead to accumulation of factor D which is the rate limiting step in complement 
activation and amplification of C3 activation. Residual renal function is having an 
important role in inflammatory process. Bolton et al has shown creatinine as a major 
determinant of interleukin 6 level in renal failure patients (12).  Elevated plasma 
levels of TNF-α and soluble TNF receptors in renal failure is correlated with severity 
of renal failure and glomerular filtration rate(13). Descamps Latscha et al 
demonstrated that there is a significant increase in plasma levels of IL 1 receptor 
antagonist from the earliest stage of renal failure. Spontaneous and lipopolysaccharide 
induced production of IL6 and IL1 in whole blood is high in dialysis patients when 
compared to general population. 
                            Acidosis in renal failure can contribute to inflammation and results 
in protein catabolism and loss of lean body mass. Fluid overload state in renal failure 
may contribute to inflammation and is having high concentration of several cytokines. 
Edematous patients are found to have elevated endotoxin levels in plasma. There is 
negative correlation between volume overload and serum albumin in patients on 
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dialysis. It is proposed that volume overload leads to increase in endotoxin and 
cytokine levels which results in reduced albumin synthesis. Attaining dry weight in 
patients on dialysis can ameliorate inflammatory response. 
Underlying comorbidity : 
          Associated comorbidity like heart failure, ischemic cardiomyopathy, diabetes 
mellitus, peripheral vascular disease can be a risk factor for inflammation and 
oxidative stress(14). Heart failure is associated with up regulation of cytokines. 
Elevated sympathetic activity in heart failure leads to enhanced cytokine response. 
TNF which is not expressed in normal myocardium is over expressed in response to 
increase in left ventricular pressure and volume overload. Reduction in TNF levels is 
documented with treatment with β blockers (15).  
Postsynthetic modification of proteins: 
           Renal failure is associated with accumulation of proinflammatory compounds 
and products of metabolism. Advanced glycation end products(AGE) and advanced 
lipoxidation end products are increased in patients with renal failure. Kidney plays an 
important role in the metabolism of advanced glycation end products. AGE can leads 
to inflammatory response by activating mononuclear cels. Inflammation also can also 
increase the production of AGE. There is a correlation between the levels of advanced 
glycation products and cytokines with severity of renal failure (16).   
Oxidative stress: 
            Renal failure decreases plasma antioxidant activity (17). Levels of IL 6, IL 1 
and TNF α are elevated in patients with renal failure. The increase in accumulation of 
uremic solutes as renal failure progress can serve as a targets for increased oxidation.  
The loss of antioxidants like zinc, selenium, vitamin C, vitamin E can occur due to 
renal failure or as a result of dialysis and can leads to increased susceptibility to 
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oxidative injury. In renal failure there are decreased levels of plasma glutathione 
peroxidase activity. Dialysis can exacerbate oxidative stress. When compared with 
healthy individuals neutrophils obtained from patients on dialysis exhibit a higher rate 
of spontaneous production of reactive oxygen species. Oxidative stress can leads to 
lipid peroxidation and oxidative alteration of lipoproteins (18). Intravenous iron 
therapy in uremic patients is a contributing factor for oxidative stress by the 
production of strong oxidant hydroxyl radical (19).  
Genetic factors: 
           Genetic factors play a role in inflammation in renal failure. Genitic factors like 
single nucleotide polymorphisms may significantly influence the immune response, 
level of inflammatory markers and prevalence of vascular calcification in patients 
with chronic renal failure. Studies have shown that genetic variation in the TNF-α 308 
and IL 10 -1082 single nucleotide polymorphisms is associated with adverse clinical 
outcome in patients with end stage renal disease (20).  
Dialysis Membrane: 
                During dialysis exposure of blood to bioincompatible dialysis membrane 
will cause activation of circulating mononuclear cells and can leads to induction of 
inflammation(21).Biocompatibility involves coagulation, thrombocytes, leucocytes, 
complement activation which results in cytokine and bradykine production and can 
leads to inflammation. Kaizu et al have shown that dialysis membrane properties 
predict the serum interleukin 6 levels in patients. Some investigators have suggested 
that even  dialysis with biocompatible membranes may pose risks for activation of 
inflammation. Interaction of circulating nuclear cells will directly stimulate cytokine 
production is suggested by the fact that during in vitro dialysis of whole blood there is 
enhanced cytokine production(22). Dialysis results in altered mononuclear cells which 
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respond more vigorously to subsequent exposure to endotoxin. Activated complement 
factors like C3a and C5a will be increased during dialysis. There is significant 
difference in complement activation with various types of membranes with cellulosic 
membrane activates more and synthetic membrane activates less complements. 
Memoli et al has shown a significant differences in the plasma levels of CRP, IL 6 
and albumin depending on the types of membrane used like cuprophan, synthetically 
modified cellulosic membranes and cellulose diacetate(23). Cells which leave 
cuprophan dialyser express large amounts of mRNA for IL 1β and IL 6 than the non 
complement activating membranes. These activated cells when stimulated 
subsequently with endotoxin ,they are sensitized to produce more cytokines.  
                      Reuse techniques and number of reuse may also contribute to the 
interaction of blood with dialyser and can lead to changes in acute phase response. 
Pyrogenic reactions in the absence of septicemia are usually closely associated with 
reuse (24).  Not only   the type of membrane ,but also its flux and convective transport 
also may influence the inflammation. Cytokine induction on the blood side of the 
membrane is the result of complement activation, the permeation of bacterial products 
from the dialysate and direct blood membrane interactions. More pro inflammatory 
products will be removed and passage of bacterial products is hindered with high flux 
membranes and convective therapies, resulting in less inflammation on the blood side. 
Dialysate Quality: 
              The water quality used for dialysis can be a contributing factor for 
inflammation. Bacterial cytokine inducing substances can be transferred from 
dialysate to the blood compartment. Cytokine inducing substances consists of a 
mixture of bacterial products.  Bacterial products like LPS, exotoxins, and 
peptidoglycans can induce cytokines and activate immune functions. These 
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substances can be detected by the biological tests of cytokine induction in peripheral 
blood mononuclear cells. It is documented that use of less than sterile dialysate or 
back leakage of lipopolysaccharide through the dialysis membranes can results in 
dialysis related inflammation.  
                     Use of  ultrapure endotoxin free water by membrane filtration of 
dialysate is associated with reduced levels of cytokines(25). These findings suggest 
that either the monocytes may be activated by endotoxin that is in the dialysate side of 
membrane or the endotoxin can directly cross the dialysis membrane. The crossing of 
the endotoxin through the dialysate membrane may be of more importance with the 
use of highly permeable membranes. When using a high flux membranes types with 
more permiability the use of cytokine inducing substances free dialysate is essential 
and supplementary measures in addition to ultra filtration may be required. Bacterial 
derived short DNA fragments can also pass through the dialyser membrane. The 
peripheral blood mononuclear cells will ingest bacterial DNA. The unmethylated 
cytosine guanosine mofits in bacterial DNA allows phagocytic cells to recognize and 
to be activated. The cytokine inducing bacterial oligonucleotides  are significantly 
small size to pass through the dialyser membranes and are not easily removed by 
conventional ultra filters. 
                         The fact that majority of patients on dialysis do not exhibit evidence 
of activation of the inflammatory response despite exposure to dialysis membranes 
and dialysates points towards the factors other than the dialysis which are specific to 
individual patients. 
Infectious cause:    
                About 15% of death in patients with end stage renal disease is attributed to 
infectious cause. Dialysis patients are at increased risk of infection as a consequence 
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of impaired humoral and cellular immunity and vascular access(26). Longitudinal 
cohort study using baseline data from the United States Renal Data system has shown 
that in a 7 year period 11.1% of nondiabetic patients and 12.5% of diabetic patients 
experienced at least one episode of septicemia (27). In this study the risk factor 
predicting septicemia were low serum albumin and advancing age. 
              Infection of the access site is very frequent and is often overlooked. Foreign 
materials in the access sites are especially liable to infection and can act as a source of 
bacteraemia. Diagnosis requires a high index of suspicion since physical signs may 
not be always present and even may require In111 white blood scans or other 
procedures. Venous catheters are associated with increased rates of infections when 
compared with other vascular access. Pastan et al had shown that medium term 
mortality and morbidity due to infections are well correlated with the use of venous 
catheters(28).  Patients with clotted vascular access are having elevated inflammatory 
markers and may play an important role in the inflammatory process. 
               Dialysis patients are also subjected to other sources of infections like 
tuberculosis especially extrapulmonory as a consequence of decreased cellular 
immunity. Peridontitis  is frequent in dialysis patients and is a common occult sourse 
of chronic inflammation that could lead to atherosclerosis and resistance to 
erythropoietic agents. Periodontal treatment can results in reduction in inflammatory 
markers (29). Associated diabetes mellitus was found to be risk factor for increased 
infection in dialysis population. Subclinical infections by microorganisms such as 
Chlamydia pneumoniae, herpes virus and combination of other factors can induce a 
micro inflammatory state in uraemic patients. Uremic patients with fluid overload 
endotoxin penetrate the intestinal mucosa and gains access to systemic circulation.  
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Consequences of micro inflammation:  
Malnutrition: 
              Despite improvement in dialysis technique and patient care the mortality is 
still high in dialysis patients when compared to general population. Previously it was 
believed that   factors related to dialysis treatment and technique were the main cause 
of poor clinical outcome. The multicenter randomized clinical trial, HEMO study 
failed to show any improvement in mortality or hospitalization by increasing dialysis 
dose or by using high flux dialysis membranes (30). Patients on maintenance dialysis 
with high rate of hospitalization and mortality, malnutrition and inflammation 
continue to be a major cause. Epidemiological studies have shown a strong 
association between malnutrition and inflammation in dialysis patients. In view of 
these two conditions coexisting in individuals with end stage renal disease the terms 
malnutrition – inflammation complex syndrome ( MICS )(31) or malnutrition 
inflammation and atherosclerosis ( MIA )(32) syndrome have been proposed. 
                           Protein energy malnutrition is defined as the state of decreased body 
pools of  protein with or without fat depletion, caused  at least partly by inadequate 
nutrient intake to nutrient demand and or which is improved by nutritional replenition. 
Protein energy malnutrition is common in dialysis patients and is risk factor for poor 
quality of life and increased morbidity and mortality including cardiovascular death. 
The prevalence of protein energy malnutrition in dialysis patients varies from 18 % to 
75% depending on the type of dialysis modality, nutritional assessment tools, and 
origin of the patient population (33). There is a good overlap in causative factors 
between malnutrition and inflammation in dialysis patients. The protein energy 
malnutrition appears to precede dialysis treatment and worsens progressively as the 
glomerular filtration decreases.  
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                  The development of protein energy malnutrition in end stage renal disease 
is secondary to inflammation. Pro inflammatory cytokines like tumor necrosis factor α 
can promote catabolic process by engendering protein degradation and by suppression 
of protein synthesis. They can also induce anorexia. Low appetite in dialysis patients 
has been associated with increased levels of inflammatory markers(34).Even in 
patients with intact appetite, are reported to develop weight loss and negative protein 
balance when there is associated inflammation due to shift in protein synthesis from 
muscle to acute phase proteins as renal function declines. In chronic kidney disease 
patients albumin synthesis is suppressed when CRP levels are elevated in serum. 
Inflammation can also lead to hypocholesterolemia which is a strong mortality risk 
factor in dialysis patients and a marker of poor nutritional status. 
Anemia:            
              Inflammation is associated with anemia and erythropoietin resistance. 
Studies have shown association between anemia and inflammation in dialysis patient 
which is reflected by high levels of CRP or other proinflammatory cytokines as IL6 
and TNF α. Serum levels of CRP, IL6 and TNF α is having a strong correlation with 
EPO doses. Stimulated mononuclear cells from dialysis patients will release 
numerous inflammatory cytokines such as IL 6, IL 1, TNF α and INF γ that may 
contribute to erythropoiesis suppression. The exact mechanism for this is not clear. 
Induction of apoptosis in erythroid progenitor cells is considered to be an important 
factor. Macrophages activated by inflammatory signals results in accelerated disposal 
of erythrocytes, shortening the life span of erythrocytes and thus decrease the HB 
concentration. 
                           Hepcidin has been implicated in patients with end stage renal disease 
as a complementary mechanism for development of anemia. Hepcidin is an 
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antimicrobial peptide synthesized in the liver. Hepcidin inhibits intestinal absorption 
of iron and is released to circulation from macrophages. Hepcidin synthesis is 
stimulated by iron overload, hypoxia and inflammation with transcription induced by 
IL 6(35).  Hepcidin may be considered as link between inflammation and anemia, 
acting as an indicator of functional iron deficiency (36).   
                     Lactoferrin is present in polmorphonuclear leukocytes. It act as a iron 
scavenger with bactericidal activity (37). During inflammation as apart of acute phase 
reaction lactoferrin synthesis increases and can bind large amount of free iron. Iron 
bound to lactoferrin is taken up by activated macrophages which express specific 
receptors for lactoferrin. During inflammation this can leads to iron deprivation of 
erythroid precursors, which is not having lactoferrin receptors. 
Cardiac effects:  
                   Cardiovascular pathology is the major cause of death in end stage renal 
disease. The incidence of cardiac death is about 5 to 10 times greater in uremic 
patients than in age matched general population. Cardiovascular death can be due to 
myocardial ischaemia, heart failure and sudden death. Approximately 40% of cardiac 
death are due to myocardial ischaemia. In the Canadian multicentre study of 432 
patients started on dialysis and prospectively followed for mean duration of 41 
months clinical signs of cardiovascular involvement were very frequent. This study 
showed heart failure 31%, coronary insuffiency 15%, angina 19%, arrhythmias 7%, 
and peripheral vascular disease 8% in the dialysis population (38).  
                   There are various cardiac effects of chronic inflammation in uraemic 
patients. The cardiac effects are summarized in table 2 
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Table 2 : Cardiac effects of chronic inflammation 
Accelerated atherogenesis 
Instability of the plaque 
Direct myodepressant activity 
Increased deposition of ground substance 
Decreased number of myocytes 
Cardiac fibrosis 
Increased heart size 
 
 
     
                           Several studies have shown the association of acute phase reactant 
proteins with cerebrovacular disease and ischaemic heart disease. The serum 
concentration of C reactive protein reflects the activity of cytokine mediated 
inflammatory process and is roughly proportional to extend of tissue injury. Owen et 
al in his studies on CRP levels in dialysis patients had shown that 35% of patients had 
values exceeding the upper limit of the reference range (39).                            
                              The excessive risk of cardiac diseases and atherosclerosis in 
chronic uraemic patients is the result of interplay between renal and non renal factors 
as well as the associated comorbidites. In uraemia the risk factors that are accepted for 
cardiovascular diseases in general population like older age, hypertension, 
hyperlipidaemia, diabetes mellitus, physical inactivity are higher. In uraemic patients 
traditional vascular risk factors are added to other factors which are specific for 
uremia and dialysis.  
                                Inflammation plays an important role in the development of 
cardiovascular damage by number of different mechanisms: ie metabolic, endothelial, 
and coagulative. Several studies have shown that inflammation per se may play an 
important role in the development of atherosclerosis and death from ischaemic heart 
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disease. As previously mentioned by Ross, atherogenesis should be considered as an 
inflammatory process.  
 
  
   
 
                         Stimulation of atherogenesis may be due to modification of lipids, 
hypercoagulation, complement activation, and endothelial dysfunction.  Apart from 
the accelerated atherogenesis, other negative effects mediated by inflammation may 
be expressed at cardiac level. 
                       Inflammation will leads to localized recruitment of neutrophils and 
monocytes.  The demonstration of activated macrophages in the cap of atherosclerotic 
plaque has led to the opinion that they contribute to plaque rupture through effects on 
matrix metalloproteinases(40). Cytokines such as TNF α and IL6 affects the 
   
Traditional 
Hypertension 
Diabetes 
Hyperlipidemia 
Smoking 
 
Uremia Related 
Acidosis 
Uremic toxins 
Free radicals 
Increased oxidized LDL
Infections 
Dialysis related 
Bioincompatibility 
Endotoxins 
Infections 
 
Proinflammatory cytokine 
release 
Increased Acute phase reactant proteins
 
Systemic inflammatory response 
 
Accelerated Atherosclerosis 
Figure 1 : Risk factors for atherosclerosis in end stage renal disease 
Endothelial dysfunction
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endothelial function and induce the endothelial expression of chemokines and 
adhesion molecules. The effects of these cytokines on triglyceride metabolism will 
further impair the endothelial generation of nitric oxide as result of raised circulating 
concentrations of non esterified  fatty acids. The effects of IL6 on platelets, fibrinogen 
and coagulation and of TNF α on the expression of plasminogen activator inhibitor by 
hepatocytes, endothelial cells and adipose tissue will lead to a procoagulant state. 
                              The microvascularization abnormalities will favor the development 
of fibrosis at the level of heart leading to increased deposition of ground substances, 
decrease in number of myocytes, and an increment in left ventricular interstitial mass. 
These abnormalities will lead to decreased capillary density and increases the distance 
of oxygen diffusion and could induce cellular ischaemia. This can lead to clinical 
signs of coronary heart disease in uraemic patients without angiographic abnormality. 
The chronic inflammatory status can results in two major cardiac alterations, the 
coronary atheromatous vascular disease and myocardial damage which will results in 
uraemic cardiomyopathy. 
                         The prevalence of coronary artery disease in end stage renal disease is 
very high.  About half of patients on maintenance dialysis have evidence of coronary 
artery disease before starting dialysis. Approximately half of the 40% patients who 
develop coronary events subsequently will do so in the first year of dialysis (41). 
There is increased frequency of complex calcified atheroma in the coronary artery of 
uraemic patients. Significantly calcified plaques have been shown in qualitative 
analyses of coronary arteries in patients with end stage renal disease. In uraemic 
patients the mean thickness of coronary artery is significantly higher when compared 
with normal population. Inflammation may modify the arterial wall and plaque 
morphology in uremic patients. Elevated plasma phosphate and increased calcium 
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phosphate products are associated with increased ectopic vascular and cardiac 
calcifications. 
                       Inflammation can also leads to calcification of atherosclerotic plaque 
and apoptosis can occur in response to inflammatory cytokines. Soluble cytokines in 
the atheroma can trigger programmed cell death, along with the T cells which is also 
involved in eliminating some smooth muscle cells. Certain T cell in plaques can 
express Fas ligands on their surface. The Fas ligand can engage Fas on the surface of 
smooth muscle cell and along with the soluble pro inflammatory cytokines it can lead 
to death of smooth muscle cells (42).  
                         Inflammation has a crucial role in thrombus formation. The release of 
inflammatory cytokines can induce endothelial activation with modification of the 
physiological properties of the endothelium and results in pro coagulant activity and 
vasoconstriction. The muscle cells will be hyperactive to the vasoconstrictive 
stimulus. There will be an increase release of metalloproteinases which will induce 
degradation of the fibrous caps, fissuration and exposure of the thrombogenic 
component of the lipid nucleus. These all will finally results in greater tendency of 
plaque instability and thrombus formation. Atheromatous plaques in uraemic patients 
are more vulnerable to rupture due to inflammation and fostering degradation of 
matrix covering the plaques. The impaired fibrogeneis associated with uremia can 
enhance this process. Uremic patients plaques are more instable than contol (41). 
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                    Considering atherosclerosis coronary artery disease in uraemic patients as 
a consequence of an inflammatory disease will provides the basis for developing new 
insights into the pathogenesis of uraemic vascular and cardiac damage. The discovery 
of reliable inflammatory markers would be helping in the pre morbid diagnosis of 
atherosclerosis and could provide a potential therapeutic end point for disease activity.  
Vascular calcification:       
                     Vascular calcification is more common and even more severe in dialysis 
patients than in general population. The arterial intimal and medial calcifications can 
constitute a significant morbidity and mortality markers that is associated with 
coronary atherosclerosis and arterial stiffness. Causes of vascular calcification in 
dialysis patients are multifactorial. Altered mineral metabolism plays a important role. 
The usual factor is the increase in serum phosphate or calcium – phosphate product. 
   Inflammation
Thrombosis
Crack and  
Fissure formation 
Vasoconstriction 
(Hyperreactive smooth 
muscle) 
Endothelial 
activation 
Figure 2 : Mechanism of thrombus formation in uraemia 
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Inverse correlation between vascular calcification inhibitors such as fetunin A and 
matrix Gla protein and the inflammatory markers has (43)shown new insights to the 
pathogeneses  of  calcification in uraemia(43).  
Insulin resistance: 
                  Peripheral insulin resistance is features of end stage renal disease (44).  
Several studies have shown that hyperglycemia and hyperinsulinemia due to insulin 
resistance may be an important contributing cause of the premature atherosclerotic 
process in uraemic patients. Accumulation of some toxic uraemic toxins is considered 
to be the cause of insulin resistance (45). The proinflammatory and proatherogenic 
cytokines like TNF α and IL6   which is accumulating as the renal function worsens is 
considered as uraemic toxins for insulin resistance. Insulin stimulated storage of 
glucose is also decreased by TNF α . When TNF α was administered to animals it 
induced insulin resistance and once it was neutralized with thiozolidinediones there 
was improvement in insulin sensitivity (46).  
                           It is documented that the features of insulin resistance syndrome such 
as increased body mass index, serum lipid levels and fasting glucose levels are linked 
to inflammation. Hak et al have shown that low grade inflammation and ICAM 1 are 
closely associated with insulin resistance in non diabetic elderly patients(47). Inverse 
relationship between insulin sensitivity and IL6 levels was shown by Fernandez Real 
et al (48). Management of low grade inflammation may be future potential target for 
treating insulin resistance in end stage renal disease. 
 
Markers of Inflammation: 
                      Recent attention has focused on the role of increased inflammation in 
promoting progression of underlying comorbid illness and thus leading to increased 
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morbidity and mortality in end stage renal disease patients. Studies have shown 
association between inflammatory markers and survival on dialysis(49). All acute 
phase reactants are markers of inflammation ( see table 3 ). 
 
Table 3 : Acute phase reactants 
Positive acute phase reactants  Negative acute phase reactants 
Proinflammatory cytokines 
     IL – 6 
     TNF – α 
     Other interleukins ( IL – 1, etc) 
Other positive acute phase reactants 
     CRP 
     Serum amyloid A 
     Ferritin 
     Fibrinogen 
     α 1 antitrypsin 
 
 
 
Nutritional markers 
     Albumin 
     Transferrin or TIBC 
     Prealbumin 
     Cholesterol 
Other negative acute phase reactants 
      Histidine rich glycoprotein 
 
                       Residual renal function is having an important role in inflammatory 
activity. There is a significant increase in serum cytokine levels with the deterioration 
of renal function. A strong positive correlation between creatinine clearance and 
various cytokines has been shown in uderdialyzed  patients with varying degree of 
renal failure(50). Reduced renal function in nephrectomized rat may affect clearance 
of TNF α and IL 1 and it has been suggested that proinflammatory cytokines actually 
could be considered as a uraemic toxin(51).  
 Albumin:    
                  Hypoalbunminemia is a powerful predictor of death in dialysis patients. 
Hypoalbuminemia has been associated with about 20 fold increase in relative risk of 
death in dialysis population(52). There is a strong evidence that inflammation plays a 
important role in determining the serum albumin level in dialysis patients(53). Both 
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CRP and cytokine levels are predictive of temporal variation in albumin levels in 
dialysis patients in cross sectional studies and they also predict survival. Albumin is 
an important negative acute phase protein. Inflammatory conditions are associated 
with decresed hepatocyte synthesis of albumin mRNA in response to cytokines. The 
finding that hepatic synthesis of albumin is increased in dialysis rules out hepatic 
disorder as cause for hypoalbuminemia in dialysis patients. Prealbumin is a highly 
sensitive marker of nutritional status in view of its rapid turn over rate and short half 
life(54).  
Ferritin :   
                   Ferritin is usually used as a marker of iron status in dialysis patients. 
However serum ferritin is also an acute phase reactant which can be increased in 
inflammatory conditions. Dialysis is associated with increased inflammation and 
about 40 – 60% of dialysis population is having elevated inflammatory markers. 
Serum ferritin results from the leakage of tissue ferritin, an intracellular iron storage 
protein which have heavy and light subunits. The level of ferritin in plasma represents 
the balance between secretion and its clearance. The liver dysfunction and 
inflammatory conditions will interfere with synthesis and clearance of ferritin, 
resulting in increased serum ferritin levels which is not related to iron metabolism.  
                       During acute phase response inflammatory cytokines will increase the 
synthesis of both H and L subunits of ferritin through an increased translation of 
preformed ferritin mRNA. This is usually associated with increased hepcidin 
activity(55). Inflammation induced hyperferritinemia may results in functional iron 
deficiency and can block iron mobility. This phenomenon may be useful in acute 
inflammation by iron containment in reticuloendothelial systems but harmful under 
chronic inflammation by causing refractory anemia in chronic kidney disease. In view 
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of since serum ferritin is an inflammatory marker, the diagnostic validity and 
reliability of serum ferritin in diagnosing anemia and iron treatment adequacy need to 
be reviewed.  
C - Reactive protein (CRP): 
                      C - Reactive protein ( CRP ) is a prominent inflammatory marker in 
dialysis patients. CRP is having a molecular weight of 115kDa with a pentamer 
structure. Function of CRP is not clearly defined, but may act as a clearance factor for 
endotoxin and opsonized bacterial products. CRP  is 5 to 10 folds higher in 
hemodialysis patients than in general population and is clearly multifactorial in orgin. 
Elevated CRP is the consequences of elevated levels of circulationg proinflammatory 
cytokines. TNF α  and IL1 isoform can  stimulate the expression of IL 6 which leads 
to the augmented expression of the CRP gene in the liver. Oxidative stress due to 
oxidized low density lipoprotein and advanced glycation end products in dialysis 
patients will stimulates cells and endothelium to produce IL6 which in turn activate 
liver to secrete CRP and other acute phase proteins such as fibrinogen and lipoprotein 
(a) .  
                             Several evidences are there showing that CRP per say may 
contribute to atherogenisis and may directly cause tissue damage. Cross sectional 
studies with single CRP values have shown that about 30 – 50 % of predialysis, 
haemodialysis, peritoneal dialysis patients have serological evidence of an activated 
inflammatory response with elevated serum CRP levels(56).  In view of short half life 
, whether changes in CRP values which are associated with intercurrent clinical 
events, influence the long term prognosis of patient on dialysis needs to be 
established.  
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Proinflammatory cytokines : 
                    Number of proinflammatory cytokines like TNF α, IL 6 and IL 1 and 
anti-inflammatory cytokines like IL 10 orchestrate the inflammatory reponse. 
Available data shows that IL 6 and its soluble receptor (sIL- 6 R ) are central 
regulators of inflammatory response. IL 6 system can leads to inflammatory events 
through the activation and proliferation of lymphocytes, differentiation of B cells, 
leukocyte recruitment and induction of the acute phase protein response in liver (57).  
                     IL 6 is a poypeptide with 22 to 27 kDa and is secreted from activated 
monocytes, macrophages, fibroblasts, adipocytes and endothelial cells in  response to 
various stimuli such as TNF α, IL -1 β, bacterial endotoxins and oxidative stress. IL 6 
acts via a receptor complex consisting of a specific IL 6 receptor and a signal 
transducing subunit ( gp130).The soluble form of receptors reach the circulation by 
shedding and regulate  the IL 6 activity. The binding of IL 6 to its receptor will 
increase the half life of IL 6 and extend the bioactivity of IL 6 to organs containing 
the gp130 membrane binding site. End stage renal disease is associated with elevated 
plasma levels of IL 6 due to loss of kidney function, fluid overload, oxidative stress, 
associated infections and dialysis related factors.  
                     Studies have shown that proinflammatory cytokines have direct 
atherogenic properties. Injection of recombinant IL 6 in apolipoprotein E deficient 
mice led to exacerbation of early atherosclerosis suggesting that IL 6 could play a 
primary role in atherosclerosis (58) . IL 6 is primary stimulant of soluble intracellular 
adhesion molecule 1 ( ICAM 1 ) which results in attachment and migration of 
leucocytes across the endothelial surface. The clinical effects of elevated IL 6 and 
strategies to reduce IL 6 should be evaluated to confirm the importance of this 
cytokine as a central mediator of inflammatory response in end stage renal disease. 
36 
 
Treatment strategies: 
                    Even though end stage renal disease is associated with high prevalence 
of chronic inflammation, little is known about its management. Although 
epidemiological studies has shown poor outcome in patients with renal insufficiency 
there is no randomized control trials to show outcome improvement with nonspecific 
inflammation reducing modalities. There is no standardized treatment strategy for 
chronic inflammation in renal insufficiency. A general principle includes treatment of 
occult infection, correction of fluid overload and management of chronic heart failure 
and coronary heart disease. 
Renin Angiotensin system inhibition: 
                       Studies has shown that angiotensin converting enzyme (ACE) 
inhibitors can suppress the production of  catabolic cytokines like TNF α and IL 1 in 
vitro  in human monocytes and in vivo in mice(59). ACE inhibitors use in end stage 
renal disease is associated with lower levels of TNF α and CRP(60). Whether the 
reduction in inflammatory markers is due to a direct suppressive effect of ACE 
inhibitors on cytokine production or an indirect effect from amelioration of heart 
failure is not clear. 
Apirin : 
                    Aspirin is known to reduce the levels of CRP and IL 6 in patient with 
coronary artery disease. Even though use of aspirin for micro inflammation in  end 
stage renal disease may be logical, the risk of bleeding should be considered.  
Generalized use of aspirin for treating micro inflammation in dialysis patient cannot 
be advocated until prospective randomized safety studies have been performed. 
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Statins :          
                     Statins are shown to have anti-inflammatory properties and have 
demonstrated reduction in CRP levels in both renal and nonrenal patients. Anti 
inflammatory property may be due to their lipid lowering effects. It has been also 
proposed that inhibition of nonsterol compounds from mevolanate may also be 
responsible for the anti inflammatory effects (61). Statins have shown to reduce both 
cardiovascular death and all cause mortality death in dialysis patients(62) . 
Subsequent large clinical trails failed to show such benifit(63)(64).  
Antioxidant :  
                Since oxidation products are mediating inflammation in end stage renal 
disease patients, use of antioxidants can modulate cytokine biology. Treatment with 
high dose viamin E supplementation reduced cardiovascular end point and myocardial 
infarction in dialysis patients(65).  Use of vitamin E coated dialyzer membrane 
resulted in reduced release of myeloperoxidase , indicating a less neutrophilic 
activation(66). In another small study use of acetylcysteine reduced the cardiovascular 
events in dialysis patients (67) . It is unclear upto what extend the beneficial effects of 
anti oxidant treatment is due to its anti inflammatory properties. 
Sevelamer :  
                   Sevelamer hydrochloride is a cationic polymer which is used as a 
intestinal phosphate binder in patients with end stage renal disease .It is having 
pleiotropic effect  of amelioration of inflammation. CRP levels was reduced on 
treatment with sevelamer(68).  
Megesterol acetate: 
                   Megesterol acetate is a synthetic derivative of progesterone and is used as 
an appetite stimulant. Megestrol acetate can inhibit the activity of IL1, IL6, TNF α 
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.The beneficial effects of using Megesterol acetate in dialysis patients are due to 
improvement in appetite, and increased dry weight and quality of life(69). The anti-
inflammatory potential of Megesterol acetate in chronic kidney disease patient needs 
to be evaluated.   
Bardoxolone methyl ( RTA 420 ): 
                    Bardoxolone methyl is an antioxidant inflammation modulator which 
inhibits immune mediated inflammation by redox homeostasis in inflamed tissue 
through the induction of cytoprotective transcription factor   NrF2 and suppress the 
activities of pro oxidant and proinflammatory  transcription factors. Bardoxolone has 
shown significant anti-inflammatory activity in various animal models inflammation 
in renal failure like ischemia reperfusion injury, renal damage in cisplatin model. 
Bardoxolone is currently under phase II clinical trial in assessing its ability to slow the 
progression of kidney disease in patients with advanced diabetic nephropathy. 
Etanercept : 
                Etanercept is an anti TNF agent. In a small pilot study on dialysis patient 
with administration of Etanercept showed only a small improvement in pre albumin 
levels (70). The effectiveness of Etanercept in improving albumin and CRP levels in 
dialysis patient is under phase II randomized double blind placebo – controlled 
clinical trial. 
Pentoxiphylline : 
               Pentoxiphylline  is a non specific phosphodiesterase inhibitor which inhibits 
TNF transcription. The anti-inflammatory and anti oxidative nutrition in dialysis 
patients (AIONID) study  which is sponsored by  National Institute of  Diabetes and 
Digestive and Kidney Disease (NIDDK) is studying the effect of  oral nutritional 
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supplements with anti-inflammatory and  antioxidant therapy along with 
Pentoxiphylline in 100 patients receiving hemodialysis.  
Anakinra: 
              Anakinra is a human recombinant IL2 receptor antagonist which is showing 
some promise in the treatment of inflammation in chronic kidney disease patients. 
Study on pharmacokinetics of anakinra in dialysis patients showed that dialysis is 
having very little effect in clearance and thrice weekly dosing may be possible (71). 
The safety and efficacy of ankinra in chronic dialysis patient is currently under 
randomized controlled clinical trial. 
Optimal dialysis treatment:  
                   Dialysis procedure itself can evoke inflammation and using biocompatible 
membrane and ultra pure dialysate can reduce the inflammatory response (72) . 
Optimization of dialysis can improve the inflammatory status of dialysis patient. 
However HEMO study failed to show a major improvement in outcome with the use 
of  high flux membranes (73). This may be due to the fact that the membrane effect on 
survival may have been small compared to other variables. Optimization of dialysis 
modality should be still considered as an important step in reducing inflammatory 
response in dialysis patients. 
 
 
 
 
 
 
40 
 
 
 
 
 
 
 
 
 
Aims  and Objectives 
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Aims: 
1. To study the association between comorbidites and outcome in maintenance 
hemodialysis patients. 
2. To asses the association between baseline inflammatory markers and outcome 
in maintenance haemodialysis patients. 
3. To assess the correlation between inflammatory markers in maintenance 
hemodialysis patients. 
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Patients and Methods 
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              This prospective observational study was conducted in the department of 
nephrology, Christian medical college, Vellore from July 2009 to December 2010. 
End stage renal disease patients who were initiated on maintenance haemodialysis in 
our dialysis unit during this period were recruited for study.   
 
Inclusion Criteria: 
1. Patients with end stage renal disease who are initiated on maintenance 
haemodialysis in our dialysis unit 
2. Age ≥ 18 years 
 
Exclusion Criteria: 
1. Patients with other inflammatory conditions like chronic infection 
2. Patients on treatment with steroids, NSAIDs  and other antiiflammatory drugs 
3. Patients positive for HBV, HCV or HIV 
4. Patients on maintenance dialysis with less than 6 months of follow up. 
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                      Based on these criteria 40 patients who were initiated on maintenance 
dialysis were enrolled for the study.  
 
Study design: 
                         This is a prospective observational study. Baseline clinical parameters 
including a detailed history and lab parameters were taken when patient is started on 
maintenance haemodialysis. Associated comorbidites was noted. Patient was divided 
into 3 groups based on the comorbidities according to Davies comorbidity scores (74). 
The comorbidity score for each patient was calculated depending on the number of 
following domains: diabetes mellitus, malignancy, ischemic heart disease, peripheral 
vascular disease, left ventricular dysfunction, systemic collagen vascular disease, and 
other significant pathology. The grade of comorbidity was obtained from the total 
scores. Grade 0 is zero score, Grade 2 is score of one or two, and Grade 3 is score of 
three or more. Information about comorbid illness was obtained from history,clinical 
examination, medical records, lab parameters, ECG and echocardiography. Patients 
were treated with thrice weekly standard bicarbonate dialysis and the clinical events 
were recorded accurately. Laboratory parameters were repeated every third month 
during follow up period. Patients were prospectively followed up during the study 
period. 
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Laboratory parameters: 
                  Blood sampling was done before the initiation of maintenance dialysis. 
Hemoglobin, WBC count, Total protein, serum albumin, urea, Creatinine, 
electrolytes, lipids, calcium, phosphate, parathyroid hormone(PTH), Ferritin, serum 
iron, TIBC were measured using standard laboratory methods. HsCRP was measured 
by commercial kit (cardiophase hsCRP, Siemens health care diagnostics, Marburg, 
Germany) by means of particle enhanced immunonephelometry. Sample for IL6, after 
centrifugation the plasma samples were stored immediately at minus 700 C until 
required for testing. IL 6 was measured using ELISA kits (BD OptEIA, BD 
Biosciences, San Jose, USA). Lab parameters were repeated every third month except 
for HsCRP and IL6 which was repeated at 6 th month. 
 
 
Statistical analyses: 
                    Data are expressed as mean ± SD or median with range. A p value of < 
0.05 was considered as statistically significant. Comparison of differences of 
categorical variables between the groups was done by chi-square test or fishers exact 
test as applicable. Comparisons of continuous variables between multiple groups were 
performed by ANOVA test or independent sample tests as applicable. Patient survival 
was analyzed by Kaplan-Meier survival analysis and log rank test was used to study 
the difference in the effect of various factors on survival. Statistical analysis and 
graphics was done using SPSS version 15, Microsoft office excel and PowerPoint 
2007.  
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The Baseline clinical and laboratory profile: 
                               The demographic profiles of the patients are shown in table 4. Male 
constituted about 77.5% of the cohort. Mean age was 52.72 ± 11.25 years. Mean BMI 
was 21.15 ± 2.44. Diabetes mellitus was present in 52.5 % and 92.5 % of patients 
were hypertensive at the time of initiation of dialysis.  Smoking history was present in 
17.5% of patients.  Mean eGFR during initiation of dialysis was 5.66 ± 2.29. Mean 
inter dialytic weight gain was 2.46 ± 0.83. Median follow up period was 310 days 
(range: 180 to 546 days) 
 
Table 4 : Demographic profiles of patients 
 
Age (years) 52.72 ± 11.25 
Males 31 ( 77.5 % ) 
Smoking history 7 ( 17.5 % ) 
Diabetes mellitus 21 ( 52.5% ) 
Hypertension 37 ( 92.5% ) 
BMI (kg/m2) 21.15 ± 2.44 
Baseline GFR (ml/min/BSA) 5.66 ± 2.29 
Inter dialystic weight gain (kg) 2.46 ± 0.83 
Urine output ( ml/day) 370 ( 100 – 1000 ) 
Median follow up days 310 ( 180 – 546 ) 
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Native Kidney Disease: 
                          Diabetic nephropathy was the commonest native kidney disease 
(47.5%) followed by unknown native kidney disease (35%), chronic 
glomerulonephritis ( 7.5%), Obstructive nephropathy (5 %), hypertensive 
nephrosclerosis (2.5%) and chronic interstitial nephritis (2.5%) (Table 5). 
 
 
Table 5: Native Kidney Disease: 
Diabetic Nephropathy 19 ( 47.5% ) 
Unknown NKD 14 ( 35 % ) 
CGN 3 ( 7.5 % ) 
CIN 1 ( 2.5% ) 
Hypertensive Nephrosclerosis 1 ( 2.5% ) 
Obstructive nephropathy 2 ( 5 % ) 
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                              Baseline laboratory profiles of patients are shown in table 6. Mean 
hemoglobin was 8.12 ± 1.70 gm/dl. Mean value of urea and Creatinine at initiation of 
dialysis was 192.59 ± 84.49 mg/dL and 11.25 ± 4.58 mg/dL respectively. The median 
value of PTH was 273 pg/ml ( range 1 – 1425) at initiation of haemodialysis. The 
mean hsCRP value was 28.5 mg/L with median value of 14.5 and range from 0.79 to 
132. The mean IL 6 value was 22.7 pgm/L with median value of 14.5 and range from 
4.2 to 119.  
Table 6 : Baseline characteristics of patients 
 
Hb (gm/dl) 8.12 ± 1.70 
Total leukocyte count(mm3) 8758 ± 3010 
Urea (mg/dL) 192.59 ± 84.49 
Creatinine (mg/dL) 11.25 ± 4.58 
Sodium (m mol/L) 132.6 ±7. 8 
Potassium (m mol/L) 4.9 ± 1.2 
Bicarbonate (m mol/L) 13.9 ± 4.2 
Calcium (mg/dL) 7.9 ± 0.9 
Phosphorus (mg/dl) 6.1 ± 2.9 
PTH (pg/ml) 273 ( 1 – 1425 ) 
Total protein (g/dL) 6.9 ± 0.8 
Albumin (g/dL) 3.7 ± 0.5 
Cholesterol (mg/dL) 164.8 ± 53.8 
Ferritin (ng/ml) 269 ( 13.6 – 2068 ) 
Serum iron  (μg/dL) 48.5 ( 10 – 223 ) 
TIBC (μg/dL) 207.1 ± 42 
HsCRP (mg/L) 14.5 ( 0.79 – 132 ) 
IL 6 (pgm/L)  14.5 ( 4.2 – 119 ) 
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                    Patients were divided into 3 groups depending on the comorbid illness 
according to davies score. The majority of patients were in grade 0 and 1 (45% in 
each group) and 10% of patients were in grade 2. The baseline characteristics of the 
three groups were similar except for statistically significant difference in age. 
 
 
Table 7 : Baseline characteristics of patients according to Davies 
score 
 
 Davies grade 0 
( n = 18 ) 
Davies grade 1 
( n = 18 ) 
Davies grade 2 
( n = 4 ) 
p 
Age (years) 48.1 ± 12.7 55.7  ± 8.5 59.7  ± 7.8 0.049 
Males 15 ( 83.3 % ) 13 ( 72.2 % ) 3 ( 75 % ) 0.863 
Smoking history 5 ( 27.8% ) 1 ( 5.6 % ) 1 ( 25 % ) 0.167 
Hypertension 17 ( 94.4 % ) 17 ( 94.4 %  ) 3 ( 75 % ) 0.443 
Diabetes Mellitus 0 17 (94.4%) 2 (50%) 0 
BMI(kg/m2) 21.1 ± 2.6 21.3 ± 2.4 20.5 ± 2.5 0.720 
Baseline GFR 4.7 ± 1.7 6.6 ± 2.6 5.2 ± 1.3 0.583 
Inter dialytic wt gain 2.35 ± 0.9 2.46 ± 0.7 2.9 ± 0.7 0.219 
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                    The baseline lab parameters of patients according to davies score is 
shown in table 8. 
Table 8 : Baseline lab parameters of patients according to Davies score 
 
 Davies grade 0 
( n = 18 ) 
Davies grade 1 
( n = 18 ) 
Davies grade 2 
( n = 4 ) 
p for 
trend 
Hb (gm/dl) 7.4 ± 1.5 8.3 ± 1.5 9.8 ± 1.9 0.088 
Tc (mm3) 8171 ± 3007 9184 ± 2940 9425 ± 3700 0.574 
Urea (mg/dL) 194.1 ± 80.5 187.6 ± 75.2 208.5 ± 100.2 0.810 
creatinine(mg/dL) 13 ± 4.6 9.6 ± 4.3 10.4 ± 2.2 0.128 
Sodium(mmol/L) 134 ± 5.2 132.1 ± 9.5 128 ± 10.4 0.368 
Potassium(mmol/L) 5 ± 1.1 4.6 ± 1.2 5.8 ± 1.5 0.370 
Hco3 (m mol/L)  13.3 ± 3.7 14.5 ± 4.4 14.2 ± 6.5 0.844 
Calcium(mg/dL) 7.5 ± 1.1 8.1 ± 0.7 8.6 ± 0.5 0.021 
Phosphorus(mg/dL) 6.9 ± 3.1 5.1 ± 2.3 6.5 ± 3.1 0.635 
PTH(pg/ml) 484 ( 24.4 -1425 ) 230 ( 13 – 781 ) 133 ( 1 – 349 ) 0.010 
Total protein(g/dL) 7.1 ± 0.7 6.9 ± 0.9 6.6 ± 0.5 0.157 
Albumin(g/dL) 3.8 ± 0.5 3.6 ± 0.5 3.3 ± 0.3 0.038 
Cholesterol(mg/dL) 159.3 ± 59.6 180.5 ± 53.5 119.5 ± 21.5 0.148 
Ferritin(ng/ml) 251 ( 64 – 2068 ) 281 ( 13 – 1650 ) 409 ( 105 – 976 ) 0.809 
Serum iron(μg/dL) 49.5 ( 10 – 223 ) 51 ( 28 – 83 ) 29.3 ± 5.6 0.014 
TIBC(μg/dL) 211 ± 46.2 209 ± 39.4 175.3 ± 26.2 0.122 
HsCRP(mg/L) 29.7 (0.9 – 132.0 ) 12.6 (0.8 – 74.7 ) 43.6 (7.2 - 123.0) 0.399 
IL 6(pgm/L) 7.8 ( 4.2 – 23 ) 16.1( 5.7 – 45.4 ) 42.4(36.9–119.0) 0.003 
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Clinical events during follow up: 
                        
                            The clinical events that occurred during the follow up time were 
documented. Hypotension was the commonest event during maintenance dialysis 
followup. 21 patients (52.5%) had one or more episode of hypotension during follow 
up. 11 patients (27.5%) had one or more episodes of infections. Six patient had sepsis 
during follow up. One patient had tuberculosis. 13 patients (32%) had one or more 
episode of pulmonary oedema during follow up period. 12 patients (30%) required at 
least one blood transfusion. 16 patients (40%) had one or more episode of AV fistula 
failure of which 8 patients (50%) had primary AVF failure. 2 patients developed 
access thrombos which were operated. One patient had fracture Lt femur which was 
corrected surgically by open reduction and internal fixation. Four patients expired 
during the follow up period of which one death was due to cardiovascular cause and 
three were infection related deaths .  
                              We analyzed the association between the baseline inflammatory 
markers and clinical events. Even though there was a trend to higher values of 
baseline inflammatory markers in clinical events like hypotension, LVF, pulmonary 
oedema, infections, AVF failure, blood transfusions, it was not statistically 
significant.   
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                       Analysis of clinical events with IL6 levels is shown in table 9. Higher 
values of IL6 were seen in patients with one or more episodes of clinical events when 
compared with those who were not having the similar events during follow up. 
 
Table 9 : Clinical events and IL 6 
EVENTS IL 6 p value 
Death Yes 52.1 ± 47.4 0.007 
No 15.7 ± 11.1 
Hypotension Yes 30.6 ± 31.2 0.065 
No 12.2 ± 8.7 
LVF & pulmonary oedema Yes 36.5 ± 36.2 0.111 
No 14.2 ± 9.6 
Infections Yes 38.5 ± 38.3 0.156 
No 14.8 ± 9.5 
AVF failure Yes 25.4 ± 32.4 0.433 
No 14.4 ± 12.6 
Blood transfusion Yes 32.1 ± 43.9 0.815 
No 19.0 ± 13.8 
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                     Analysis of clinical events with hsCRP levels is shown in table 10. Higher 
values of hsCRP were seen in patients with one or more episodes of  clinical events 
when compared with those who were not having the similar events during follow up. 
 
 
Table 10 : Clinical events and hsCRP 
EVENTS hsCRP p value 
Death Yes 62.1 ± 48.2 0.038 
No 24.7 ± 31.3 
Hypotension Yes 24.2 ± 29.5 0.394 
No 33.3 ± 39.6 
LVF & pulmonary oedema Yes 45.6 ± 45.4 0.091 
No 20.2 ± 24.9 
Infections Yes 42.4 ± 44.7 0.148 
No 22.5 ± 28.0 
AVF failure Yes 24.5 ± 31.5 0.515 
No 28.8 ± 37.2 
Blood transfusion Yes 40.6 ± 49.6 0.535 
No 23.9 ± 26.5 
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                We analyzed the correlation between IL6 and hsCRP. A strong positive 
correlation was seen between hsCRP and IL 6 levels as shown in figure 3.  The 
correlation between IL6 and hsCRP showed r square value of 0.853 with p value of 
0.002.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Correlation between IL6 and hsCRP 
p= 0.002 
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                           Correlation of other acute phase reactants with IL6 and hsCRP was 
measured. Total WBC count was having significant correlation with IL6 and hsCRP. 
There was a negative correlation between IL6 and hsCRP with albumin, but was not 
statistically significant. Serum ferritin level did not show any significant correlation 
with IL6 and hsCRP.  
 
 
Table 11: Correlation between different inflammatory markers 
 IL6 hsCRP WBC count albumin ferritin 
IL6  .924 .493 −.324 .244 
hsCRP .924  .492 −.205 .061 
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                      The association between the baseline parameters and mortality was 
analyzed. Baseline IL6 (p value .007) , hsCRP levels (p value .038), and total 
leukocyte count (p value .006)  was significantly different between the death and alive 
group.   
Table 12: Parameters of alive and dead patient groups 
Parameters Alive Dead p 
Age (years) 51.7 ± 11.1 61.7 ± 8.5 0.091 
Diabetes Mellitus 17 2 0.916 
Hypertension 33 4 0.548 
BMI (kg/m2) 21.1 ± 2.5 21.1 ± 0.6 0.984 
Baseline GFR(ml/min/BSA) 5.6 ± 2.3 5.5 ± 1.5 0.944 
Hb (gm/dl) 8.1 ± 1.6 8.2 ± 2.1 0.886 
TC (mm3) 8285 ± 2461 13166 ± 4743 0.006 
Sodium(m mol/L) 133 ± 7 129 ± 10 0.330 
Potassium (m mol/L) 4.8 ± 1.1 5.8 ± 1.6 0.117 
Bicarbonate (m mol/L) 14.2 ± 4.1 11.5 ± 4.6 0.227 
Albumin (g/dL) 3.7 ± 0.5 3.5 ± 0.2 0.417 
Cholesterol (mg/dL) 166.7 ± 54.5 139.5 ± 50.2 0.500 
Calcium (mg/dL) 7.8 ± 0.9 8.1 ± 0.8 0.539 
Phosphorus (mg/dL) 5.9 ± 2.8 7.0 ± 2.1 0.474 
PTH (pg/ml) 383 ± 312 223 ± 142 0.391 
Ferritin (ng/ml) 401 ± 236 632 ± 302 0.379 
IL6 (pgm/L) 15.7 ± 11.1 52.1 ± 47.4 0.007 
hsCRP (mg/L) 24.7 ± 31.3 62.1 ± 48.2 0.038 
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Patient Survival rates: 
                         Baseline IL6, hsCRP levels and total leukocyte count was 
significantly different between the death and alive patient groups. The receiver 
operating characteristic (ROC) curves of IL 6, hsCRP and total leukocyte count was 
done and cut off points related to mortality was determined. The best predictive value 
for CRP was 36.3mg/L (sensitivity 75% and specificity 81.6%). The best predictive 
value of IL 6 was 34.5pgm/L (sensitivity 75% and specificity 94%). The best 
predictive value of WBC count was 7500 (sensitivity 100% and specificity 40%). 
Kaplan Meier survival analysis showed there is a significant difference in survival 
between the patients with the different base line level of inflammatory markers. 
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                       The receiver operating characteristic (ROC) curves of IL 6 showed 
value of 34.5pgm/L (sensitivity 75% and specificity 94%) as best predictive cut off 
points related to mortality as shown in figure 4. 
 
Figure 4: ROC curve of IL6 and Mortality.
AUC = 0.79 (0.47-1.12) 
p = 0.073 
IL6 = 34.5 
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                     Kaplan Meier survival analysis of patients with IL6 value cut off of 34.5 
pgm /ml  is shown in figure 5. There is a significant difference in survival between the 
patients with IL6 values below 34.5 pgm/ml and ≥  34.5 pgm/ml.  
 
 
 
 
 
 
Figure 5: Patient survival based on IL6 values. 
 
 
 
    
 
 
 
 
 
 
 
 
IL6 < 34.5 
IL6 ≥ 34.5 
Log rank p = 0.001 
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                     The receiver operating characteristic (ROC) curves of hsCRP showed 
value of  36.3mg/L ( sensitivity 75% and specificity 81.6%) as best predictive cut off 
points related to mortality  as shown in figure 6 . 
 
Figure 6: ROC curve for hsCRP and mortality. 
AUC = 0.77 (0.52-1.01) 
p = 0.083 
hsCRP 36.3 
hsCRP 10.0 
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                    Kaplan Meier survival analysis of patients with hsCRP value cut off of 
36.3mg/L is shown in figure 7. There is a significant difference in survival between 
the patients with hsCRP values below 36.3mg/L and ≥ 36.3mg/L. 
 
 
 
Figure 7: Patient survival with hsCRP cutoff of 36.3 mg/L. 
 
 
 
hsCRP < 36.3 
hsCRP ≥ 36.3
Log rank p = 0.007 
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               Kaplan Meier survival analysis of patients with hsCRP value cut off of 
10mg/L is shown in figure 8. 
 
 
Figure 8: Patient survival with hsCRP cutoff of 10 mg/L.
hsCRP <  10 
hsCRP ≥ 10 
Log rank p = 0.167 
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                             The receiver operating characteristic (ROC) curves of total 
leukocyte count showed value of  7500 mm3( sensitivity 100% and specificity 40%) 
as best predictive cut off points related to mortality  as shown in figure 9. 
 
 
Figure 9: ROC curve for total leucocyte count and mortality 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AUC = 0.80 (0.47-1.13) 
p = 0.095 
TC =7500
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                           Kaplan Meier survival analysis of patients with total leukocyte cut 
off of 7500 mm3 is shown in figure 10. There is a significant difference in survival 
between the patients with total leukocyte count below 7500 and ≥ 7500 mm3. 
 
 
 
 
Figure 10: Patient survival with baseline leukocyte count. 
 
 
 
 
 
 
 
 
 
TC < 7500 
TC ≥ 7500 
Log rank p = 0.288 
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Discussion 
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              The cause for low life expectancy of patients on maintenance dialysis is 
multifactorial (75) . Higher age group, associated comorbid illness and increased 
inflammation are considered to be a major factor for decreased life expectancy.  
age: 
                     Increasing age is associated with reduced survival in patients on 
maintenance haemodialysis. The mean age at initiation of maintenance dialysis in our 
study population was 52.72 ± 11.25 years. Patients below 45 years will do better on 
dialysis when compared with older age groups (76). Our study showed patients who 
died were having higher mean age (61.7 ± 8.5) at initiation of dialysis, when 
compared with patient continuing on maintenance haemodialysis.  
Cormorbid illness: 
                 Associated comorbid illness is more prevalent in new patients starting on 
dialysis when compared with previous years (77). 55% of our patients started on 
maintenance dialysis were having one or more comorbid illness. Patient with other 
comorbid illness is associated with poor outcome on maintenance haemodialysis. End 
stage renal disease patients with cardiovascular disease, diabetes mellitus, and 
peripheral vascular disease will have more fluid overload with sympathetic over 
activity and increased inflammation which may be the reason for poor outcome of 
these patients on maintenance dialysis. 
                        In 2007 United States Renal Data System Annual Report, diabetes 
mellitus was shown as the leading cause of end stage renal disease for patients 
initiated on maintenance dialysis which was 44%.In our study diabetic nephropathy 
was the native kidney disease in 47.5% of patients. Studies have shown prevalence of 
hypertension during the onset of dialysis is about 80% (78). In our study hypertension 
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was present in 92.5% of patients. Poorly controlled hypertensive patients had a greater 
interdialytic weight gain and poor fluid control status which is associated with 
increased mortality and morbidity.  
                        Cardiovascular disease is very common in dialysis patients. In the 
HEMO study about 80% of patients were having some form of cardiac disease of 
which 40% were ischemic cardiac disease (79) . Cardiovascular disease accounts for 
about 50% of death in end stage renal disease. Choices for healthy outcome in caring 
for ESRD (CHOICE) study have shown that a large percentage of incident dialysis 
patients have various traditional risk factor for cardiovascular disease (80) . CHOICE 
study showed in patients initiated on dialysis diabetes mellitus was present in 54%, 
hypertension in 96%, low HDL in 33%, and increased age with mean age of about 60 
years. In our study diabetes mellitus was present in 52.5% and hypertension in 92.5% 
and low serum HDL in 39.6% of patients. In dialysis patients the chronic 
inflammation in vessels can lead to accelerated atheroma formation with erosion and 
fissuration of plaques which can lead to rupture of plaques. The increased 
cardiovascular mortality in dialysis patient may be attributed to same reason.   
Comorbidity index:  
                                Various comorbid indices have been used for predicting mortality 
in end stage renal disease patients (81). In our study we used we used the Davies 
comorbidity index which have been shown to be a good semi-quantitative predictor of 
mortality in chronic kidney disease patients (82). Associated comorbid illness were 
associated with poor outcome in dialysis patients (83) .As shown in our study patients 
with higher grades of comorbidities was associated with higher mortality and 
morbidity. Further studies are needed to identify and weight the comorbidity variables 
for accurate risk assessment. 
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Inflammation:  
                   Chronic kidney disease is a chronic inflammatory state. The inflammatory 
cascade can account for anorexia, decreased skeletal muscle protein synthesis and 
increased catabolism. These can explain the increased association of malnutrition in 
end stage renal disease and dialysis population. Control of chronic inflammation can 
improve nutritional status of these patients.  There is a strong association between 
malnutrition and inflammation and both of which can lead to poor outcome in patients 
on maintenance haemodialysis.  
 
Microinflammatory markers:        
                   Studies have shown that about 30 to 60% of patients on dialysis have 
increased inflammatory markers (84). Increased inflammatory markers in dialysis 
patients strongly predict all cause and cardiovascular mortality(84,85). Since 
inflammatory markers are actively involved in pathogenesis of athero-
thrombogenesis, elevated inflammatory markers should be considered as a risk factors 
for the same (86). Inflammatory markers are not only risk markers but also a risk 
factor for poor outcome in dialysis population.  The cause of elevated inflammatory 
markers in end stage renal disease may be due to impaired clearance of uraemic 
toxins, associated comorbid conditions, chronic infections and other unknown factors.  
Our study has shown that higher baseline inflammatory markers were associated with 
higher mortality. There was a significant difference in survival when we compared the 
patients with inflammatory markers above and below the cut off value predictive of 
mortality. There was also a trend to higher baseline inflammatory markers in other 
clinical events like hypotension, LVF, pulmonary oedema, infections, AVF failure, 
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blood transfusions, but it was not statistically significant. This may be due to the fact 
that the study sample was small. Larger trials may be needed to decide on utility of 
these markers in predicting the morbidity in maintenance dialysis population.  
                        IL6 and hsCRP were having good positive correlation. Other acute 
phase reactants did not show statistically significant correlation. The measurement of 
inflammatory markers can be routinely used in patients initiated on maintenance 
haemodialysis  for risk stratification and prognostification. 
 
Clinical events: 
               Hypotension was the commonest events during follow up which occurred in 
about 50% of patients. One or more infection episode was present in about 25% of 
patients during follow up. Sepsis and access related infection was the commonest 
cause of infection in these patients.  Infections can exacerbate the preexisting chronic 
inflammation and can leads to poor outcome.  About 40% of patients had one or more 
episodes of AV fistula failure. Chronic inflammation and increased athero-
thrombogenesis may be the reason for increased vascular access failure in these 
groups of patients.  
Mortality: 
              There was a significant difference in total leukocyte counts, IL6 and hsCRP 
levels between the patients who died during follow up.  Baseline inflammatory 
markers levels can be used as predictive markers for poor outcome in patients on 
maintenance haemodialysis. The higher cutoff values for mortality predictor in our 
haemodialysis patients may be due to higher baseline chronic inflammation associated 
with increased infection and fluid overload in these patients.  
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                            Conclusions 
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 Conclusions: 
1. Comorbid illness is associated with poor outcome in patients initiated on 
maintenance dialysis   
2. Presence of higher baseline inflammatory markers levels is a poor prognostic 
marker in maintenance dialysis patients 
3. IL 6 value of more than 34.5pgm/L is predictive of mortality with sensitivity 
of 75% and specificity 94%. 
4. HsCRP value of more than 36.3mg/L is predictive of mortality with sensitivity 
of 75% and specificity 81.6%. 
5. There is a strong positive correlation between CRP and IL 6 levels 
6. Our study highlights the fact that measurement of baseline inflammatory 
markers level should be considered for patients initiating on maintenance 
dialysis for risk stratification. 
 
73 
 
  
 
 
 
Bibliography 
74 
 
 
Bibliography: 
1. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, et al. C-
reactive protein and albumin as predictors of all-cause and cardiovascular 
mortality in chronic kidney disease. Kidney Int. 2005;68(2):766-772.  
 
2. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, et al. 
Immunologic function and survival in hemodialysis patients. Kidney Int. 1998 
Jul;54(1):236-244.  
 
3. Elhage R, Clamens S, Besnard S, Mallat Z, Tedgui A, Arnal J, et al. Involvement 
of interleukin-6 in atherosclerosis but not in the prevention of fatty streak 
formation by 17beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis. 
2001 Jun;156(2):315-320.  
 
4. Lawrence Y. Agodoa, Paul W. Eggers. Renal replacement therapy in the United 
States: Data from the United States renal data system. Am J Kidney Dis. 1995 Jan 
1;25(1):119-133.  
 
5. Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, et al. 
Mortality and hospitalization in haemodialysis patients in five European 
countries: results from the Dialysis Outcomes and Practice Patterns Study 
(DOPPS). Nephrology Dialysis Transplantation. 2004 Jan 1;19(1):108 -120.  
 
6. RN Foley, PS Parfrey, MJ Sarnak. Clinical epidemiology of cardiovascular 
disease in chronic renal disease. Am J Kidney Dis. 1998 Nov 1;32(5):S112-S119.  
 
7. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation 
enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 
1999 Feb;55(2):648-658.  
 
8. Eiji Ishimura, Tetsuo Shoji, Masanori Emoto, Kouka Motoyama, Kayo Shinohara, 
Naoki Matsumoto, et al. Renal insufficiency accelerates atherosclerosis in patients 
with type 2 diabetes mellitus. Am J Kidney Dis. 2001 Oct 1;38(4):S186-S190.  
 
9. Ross R. Atherosclerosis--an inflammatory disease. N. Engl. J. Med. 1999 Jan 
14;340(2):115-126.  
 
10. Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, et al. 
Fibrinogen, mortality and incident cardiovascular complications in end-stage 
renal failure. J. Intern. Med. 2003 Aug;254(2):132-139.  
 
11. Stenvinkel P. Inflammation in end‐stage renal failure: could it be treated? 
Nephrology Dialysis Transplantation. 2002;17(suppl 8):33 -38.  
 
12. Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, et al. 
Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and 
pro-inflammatory cytokines. Nephrol. Dial. Transplant. 2001 Jun;16(6):1189-
75 
 
1197.  
 
13. Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, 
Moynot A, et al. Balance between IL-1 beta, TNF-alpha, and their specific 
inhibitors in chronic renal failure and maintenance dialysis. Relationships with 
activation markers of T cells, B cells, and monocytes. J. Immunol. 1995 Jan 
15;154(2):882-892.  
 
14. Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential 
consequences. Semin. Nephrol. 2004 Sep;24(5):469-473.  
 
15. Ohtsuka T, Hamada M, Hiasa G, Sasaki O, Suzuki M, Hara Y, et al. Effect of 
beta-blockers on circulating levels of inflammatory and anti-inflammatory 
cytokines in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 2001 
Feb;37(2):412-417.  
 
16. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen 
AT, Canteloup S, et al. Advanced oxidation protein products as novel mediators 
of inflammation and monocyte activation in chronic renal failure. J. Immunol. 
1998 Sep 1;161(5):2524-2532.  
 
17. Mimić-Oka J, Simić T, Djukanović L, Reljić Z, Davicević Z. Alteration in plasma 
antioxidant capacity in various degrees of chronic renal failure. Clin. Nephrol. 
1999 Apr;51(4):233-241.  
 
18. Paul JL, Sall ND, Soni T, Poignet JL, Lindenbaum A, Man NK, et al. Lipid 
peroxidation abnormalities in hemodialyzed patients. Nephron. 1993;64(1):106-
109.  
 
19. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais 
SJ, et al. Iron Therapy, Advanced Oxidation Protein Products, and Carotid Artery 
Intima-Media Thickness in End-Stage Renal Disease. Circulation. 2002 Oct 
22;106(17):2212-2217.  
 
20. Stenvinkel P, Pecoits-Filho R, Lindholm B. Gene polymorphism association 
studies in dialysis: the nutrition-inflammation axis. Semin Dial. 2005 
Aug;18(4):322-330.  
 
21. Honkanen E, Gr&ouml;nhagen-Riska C, Teppo A, Maury C, Meri S. Acute-Phase 
Proteins during Hemodialysis: Correlations with Serum Interleukin-1&beta; 
Levels and Different Dialysis Membranes. Nephron. 1991;57(3):283-287.  
 
22. Pereira BJ, Snodgrass B, Barber G, Perella C, Chopra S, King AJ. Cytokine 
production during in vitro hemodialysis with new and formaldehyde- or renalin-
reprocessed cellulose dialyzers. J. Am. Soc. Nephrol. 1995 Oct;6(4):1304-1308.  
 
23. Memoli B, Minutolo R, Bisesti V, Postiglione L, Conti A, Marzano L, et al. 
Changes of serum albumin and C-reactive protein are related to changes of 
interleukin-6 release by peripheral blood mononuclear cells in hemodialysis 
patients treated with different membranes. Am. J. Kidney Dis. 2002 
76 
 
Feb;39(2):266-273.  
 
24. Ismail N, Becker BN, Hakim RM. Water Treatment for Hemodialysis. Am J 
Nephrol. 1996;16(1):60-72.  
 
25. Bambauer R, Walther J, Jung W. Ultrafiltration of Dialysis Fluid to Obtain a 
Sterile Solution during Hemodialysis. Blood Purif. 1990;8(6):309-317.  
 
26. Vanholder R, Ringoir S, Dhondt A, Hakim R. Phagocytosis in uremic and 
hemodialysis patients: a prospective and cross sectional study. Kidney Int. 1991 
Feb;39(2):320-327.  
 
27. Jaar BG, Hermann JA, Furth SL, Briggs W, Powe NR. Septicemia in diabetic 
hemodialysis patients: comparison of incidence, risk factors, and mortality with 
nondiabetic hemodialysis patients. Am. J. Kidney Dis. 2000 Feb;35(2):282-292.  
 
28. Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death 
among hemodialysis patients. Kidney Int. 2002 Aug;62(2):620-626.  
 
29. Kadiroglu AK, Kadiroglu ET, Sit D, Dag A, Yilmaz ME. Periodontitis is an 
important and occult source of inflammation in hemodialysis patients. Blood 
Purif. 2006;24(4):400-404.  
 
30. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. 
Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis. New 
England Journal of Medicine. 2002 Dec 19;347(25):2010-2019.  
 
31. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A malnutrition-
inflammation score is correlated with morbidity and mortality in maintenance 
hemodialysis patients. Am. J. Kidney Dis. 2001 Dec;38(6):1251-1263.  
 
32. Pecoits‐Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and 
atherosclerosis (MIA) syndrome – the heart of the matter. Nephrology Dialysis 
Transplantation. 2002 Nov 1;17(suppl 11):28 -31.  
 
33. Mehrotra R, Kopple JD. Nutritional management of maintenance dialysis 
patients: why aren't we doing better? Annu. Rev. Nutr. 2001;21:343-379.  
 
34. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD. 
Appetite and inflammation, nutrition, anemia, and clinical outcome in 
hemodialysis patients. The American Journal of Clinical Nutrition. 
2004;80(2):299 -307.  
 
35. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin 
transcription by interleukin-1 and interleukin-6. Proc. Natl. Acad. Sci. U.S.A. 
2005 Feb 8;102(6):1906-1910.  
 
36. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. 
Inappropriate expression of hepcidin is associated with iron refractory anemia: 
implications for the anemia of chronic disease. Blood. 2002 Nov 
77 
 
15;100(10):3776-3781.  
 
37. Jurado RL. Iron, infections, and anemia of inflammation. Clin. Infect. Dis. 1997 
Oct;25(4):888-895.  
 
38. Bloembergen WE. Cardiac disease in chronic uremia: epidemiology. Adv Ren 
Replace Ther. 1997 Jul;4(3):185-193.  
 
39. Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal 
disease: where do we start? Am. J. Kidney Dis. 1998 Nov;32(5 Suppl 3):S5-13.  
 
40. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix 
metalloproteinases and matrix degrading activity in vulnerable regions of human 
atherosclerotic plaques. J Clin Invest. 1994 Dec;94(6):2493-2503.  
 
41. Goldsmith DJ, Covic A. Coronary artery disease in uremia: Etiology, diagnosis, 
and therapy. Kidney Int. 2001 Dec;60(6):2059-2078.  
 
42. Geng YJ, Henderson LE, Levesque EB, Muszynski M, Libby P. Fas is expressed 
in human atherosclerotic intima and promotes apoptosis of cytokine-primed 
human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 1997 
Oct;17(10):2200-2208.  
 
43. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, et al. 
Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of 
malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am. J. 
Kidney Dis. 2006 Jan;47(1):139-148.  
 
44. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin 
resistance in uremia. J Clin Invest. 1981 Feb;67(2):563-568.  
 
45. Alvestrand A. Carbohydrate and insulin metabolism in renal failure. Kidney Int. 
Suppl. 1997 Nov;62:S48-52.  
 
46. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance 
and type 2 diabetes. Trends Endocrinol. Metab. 2000 Aug;11(6):212-217.  
 
47. Hak AE, Pols HAP, Stehouwer CDA, Meijer J, Kiliaan AJ, Hofman A, et al. 
Markers of Inflammation and Cellular Adhesion Molecules in Relation to Insulin 
Resistance in Nondiabetic Elderly: The Rotterdam Study. J Clin Endocrinol 
Metab. 2001 Sep 1;86(9):4398-4405.  
 
48. Fernandez-Real J, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, et al. 
Circulating Interleukin 6 Levels, Blood Pressure, and Insulin Sensitivity in 
Apparently Healthy Men and Women. J Clin Endocrinol Metab. 2001 Mar 
1;86(3):1154-1159.  
 
49. Tripepi G, Mallamaci F, Zoccali C. Inflammation Markers, Adhesion Molecules, 
and All-Cause and Cardiovascular Mortality in Patients with ESRD: Searching for 
the Best Risk Marker by Multivariate Modeling. Journal of the American Society 
78 
 
of Nephrology. 2005 Mar 1;16(3 suppl 1):S83 -S88.  
 
50. van Riemsdijk-van Overbeeke IC, Baan CC, Hesse CJ, Loonen EH, Niesters HG, 
Zietse R, et al. TNF-alpha: mRNA, plasma protein levels and soluble receptors in 
patients on chronic hemodialysis, on CAPD and with end-stage renal failure. Clin. 
Nephrol. 2000 Feb;53(2):115-123.  
 
51. Bemelmans MH, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor 
necrosis factor clearance in a murine model. J. Immunol. 1993 Mar 
1;150(5):2007-2017.  
 
52. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of 
commonly measured variables and an evaluation of death rate differences 
between facilities. Am. J. Kidney Dis. 1990 May;15(5):458-482.  
 
53. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, et al. 
Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in 
hemodialysis patients. Am. J. Kidney Dis. 1998 Jul;32(1):107-114.  
 
54. Mears E. Outcomes of continuous process improvement of a nutritional care 
program incorporating serum prealbumin measurements. Nutrition. 1996 
Aug;12(7-8):479-484.  
 
55. Barisani D, Pelucchi S, Mariani R, Galimberti S, Trombini P, Fumagalli D, et al. 
Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic 
Iron Overload. J. Hepatol. 2008 Jul;49(1):123-133.  
 
56. Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, et al. 
Strong association between malnutrition, inflammation, and atherosclerosis in 
chronic renal failure. Kidney Int. 1999 May;55(5):1899-1911.  
 
57. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The 
Pathophysiologic Roles of Interleukin-6 in Human Disease. Annals of Internal 
Medicine. 1998 Jan 15;128(2):127 -137.  
 
58. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates 
early atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 1999 
Oct;19(10):2364-2367.  
 
59. Fukuzawa M, Satoh J, Sagara M, Muto G, Muto Y, Nishimura S, et al. 
Angiotensin converting enzyme inhibitors suppress production of tumor necrosis 
factor-alpha in vitro and in vivo. Immunopharmacology. 1997 Apr;36(1):49-55.  
 
60. Stenvinkel P, Andersson P, Wang T, Lindholm B, Bergström J, Palmblad J, et al. 
Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced 
chronic renal failure? J. Intern. Med. 1999 Nov;246(5):503-507.  
 
61. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, et al. 
In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate 
products. Arterioscler. Thromb. Vasc. Biol. 2001 Aug;21(8):1327-1332.  
79 
 
 
62. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, et al. 
HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD 
patients. Kidney Int. 2002 Jan;61(1):297-304.  
 
63. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et 
al. Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. 
N Engl J Med. 2009 4;360(14):1395-1407.  
 
64. Wanner C, Krane V, März W, Olschewski M, Mann JFE, Ruf G, et al. 
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. 
Engl. J. Med. 2005 Jul 21;353(3):238-248.  
 
65. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al. Secondary 
prevention with antioxidants of cardiovascular disease in endstage renal disease 
(SPACE): randomised placebo-controlled trial. Lancet. 2000 Oct 
7;356(9237):1213-1218.  
 
66. Omata M, Higuchi C, Demura R, Sanaka T, Nihei H. Reduction of neutrophil 
activation by vitamin E modified dialyzer membranes. Nephron. 2000 
Jul;85(3):221-231.  
 
67. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant 
acetylcysteine reduces cardiovascular events in patients with end-stage renal 
failure: a randomized, controlled trial. Circulation. 2003 Feb 25;107(7):992-995.  
 
68. Yamada K, Fujimoto S, Tokura T, Fukudome K, Ochiai H, Komatsu H, et al. 
Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance 
hemodialysis patients. Ren Fail. 2005;27(4):361-365.  
 
69. Rammohan M, Kalantar-Zadeh K, Liang A, Ghossein C. Megestrol acetate in a 
moderate dose for the treatment of malnutrition-inflammation complex in 
maintenance dialysis patients. J Ren Nutr. 2005 Jul;15(3):345-355.  
 
70. Don BR, Kim K, Li J, Dwyer T, Alexander F, Kaysen GA. The effect of 
etanercept on suppression of the systemic inflammatory response in chronic 
hemodialysis patients. Clin. Nephrol. 2010 Jun;73(6):431-438.  
 
71. Yang B, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with 
different levels of renal function. Clin. Pharmacol. Ther. 2003 Jul;74(1):85-94.  
 
72. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response 
to recombinant human erythropoietin in haemodialysis patients. Nephrol. Dial. 
Transplant. 2000 Aug;15(8):1207-1211.  
 
73. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. 
Effect of dialysis dose and membrane flux in maintenance hemodialysis. N. Engl. 
J. Med. 2002 Dec 19;347(25):2010-2019.  
 
74. Davies SJ, Phillips L, Naish PF, Russell GI. Quantifying comorbidity in 
80 
 
peritoneal dialysis patients and its relationship to other predictors of survival. 
Nephrology Dialysis Transplantation. 2002 Jun 1;17(6):1085 -1092.  
 
75. Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, et al. 
Excerpts From the US Renal Data System 2009 Annual Data Report. Am J 
Kidney Dis. 2010 Jan;55(1 Suppl 1):S1-A7.  
 
76. Mailloux LU, Bellucci AG, Napolitano B, Mossey T, Wilkes BM, Bluestone PA. 
Survival estimates for 683 patients starting dialysis from 1970 through 1989: 
identification of risk factors for survival. Clin. Nephrol. 1994 Aug;42(2):127-135.  
 
77. Miskulin D, Bragg-Gresham J, Gillespie BW, Tentori F, Pisoni RL, Tighiouart H, 
et al. Key Comorbid Conditions that Are Predictive of Survival among 
Hemodialysis Patients. Clinical Journal of the American Society of Nephrology. 
2009 Nov 1;4(11):1818 -1826.  
 
78. Zucchelli P, Santoro A, Zuccala A. Genesis and control of hypertension in 
hemodialysis patients. Semin. Nephrol. 1988 Jun;8(2):163-168.  
 
79. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, et al. 
Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO 
Study. Kidney Int. 2004 Jun;65(6):2380-2389.  
 
80. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, et al. 
Traditional cardiovascular disease risk factors in dialysis patients compared with 
the general population: the CHOICE Study. J. Am. Soc. Nephrol. 2002 
Jul;13(7):1918-1927.  
 
81. van Manen JG, Korevaar JC, Dekker FW, Boeschoten EW, Bossuyt PMM, 
Krediet RT. How to adjust for comorbidity in survival studies in ESRD patients: a 
comparison of different indices. Am. J. Kidney Dis. 2002 Jul;40(1):82-89.  
 
82. Caravaca F, Martín MV, Barroso S, Ruiz B, Hernández-Gallego R. Do 
inflammatory markers add predictive information of death beyond that provided 
by age and comorbidity in chronic renal failure patients? Nephrology Dialysis 
Transplantation. 2006 Jun;21(6):1575 -1581.  
 
83. Khan I. Influence of coexisting disease on survival on renal-replacement therapy. 
The Lancet. 1993 2;341(8842):415-418.  
 
84. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-
cause and cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 
2000 Mar;35(3):469-476.  
 
85. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation 
enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 
1999 Feb;55(2):648-658.  
 
86. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J. Clin. Invest. 
2003 Jun;111(12):1805-1812.  
81 
 
 
Appendices 
82 
 
PROFORMA 
(A)  PATIENT CHARACTERISTICS 
 
Name: 
Age (years):                       Height:                   Weight:                 BMI: 
Sex: M = 0, F = 1                                               Smoking : Y/N    
Address:                                                                                                Phone: 
 
Occupation:  
Hospital number: 
Native Kidney Disease 
Renal biopsy done: Yes/No 
e GFR –                       Daily Urine output :               
Associated comorbidites pre HD  
DISEASE Y/N DURATION DISEASE Y/N DURATION 
DIABETES MELLITUS   COPD   
HYPERTENSION   INFECTIONS   
LVF   MALIGNANCY   
IHD   OTHERS   
PVD      
CONNECTIVE TISSUE DIS      
 
DRUGS: - ASPIRIN-Y/N,    ACE/ARB-Y/N,    STATINS-Y/N, 
 ERYTHROPOETIN- Y/N  (weekly dose                 ),                  PARENTERAL IRON (dose              ) 
 
Date of initiation of Hemodialysis:                            Thrice/Twice Weekly,  Duration:  
 Y/N DURATION  Y/N DURATION 
JUGULAR CATH   FEMORAL CATH   
SUBCLAVIAN CATH   AV FISTULA/GRAFT   
 
Lab Parameters Pre HD 3rd month 6th month 9th month 12th month 15th month 18th month 
HB        
Total count        
TP/Serum Albumin        
Lipids        
Na/K/Hco3        
Bicarbonate        
Ca/Po4/        
PTH        
Serum Ferritin        
Uric acid        
Hs CRP        
IL-6        
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Intercurrent clinical events 
EVENTS Y/N EPISODES EVENTS Y/N EPISODES 
HYPOTENSION   ACCESS THROMBOSIS   
LVF   ACCESS INFECTION   
CORONARY DISEASE   INFECTIONS   
ARRYTHMIAS   OTHERS   
CVA      
BLOOD TRANSFUSION      
      
 
Notes - 
 
 
 
